Healthcare / Medical Instruments & SuppliesKOSDAQ
$6020.00
-80.00 (-1.31%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $6.5B · quality 60.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$42.7B
P/E
6.5x
↓EV/EBITDA
3.8x
↓ROE
15.5%
↑Gross Margin
50.5%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.6%
FCF CAGR
—
FCF margin
18.3%
FCF / Net income
0.98x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $35.24B · net income $6.62B · FCF $6.46B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $35.24B | $35.24B | $30.44B | $29.61B | $26.75B |
| Net Income | $6.62B | $6.62B | $5.69B | $5.50B | $3.21B |
| EBITDA | $9.33B | $9.33B | $8.13B | $8.84B | $6.14B |
| EPS | 933.00 | 933.00 | 4010.00 | 725.00 | 445.00 |
| Gross Margin | 50.5% | 50.5% | 46.9% | 47.9% | 46.6% |
| Operating Margin | 23.2% | 23.2% | 21.0% | 24.1% | 19.3% |
| Net Margin | 18.8% | 18.8% | 18.7% | 18.6% | 12.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.23 | 0.34 |
| Current Ratio | 4.31 | 4.31 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $6.46B | $6.46B | $8.18B | $3.10B | $-786.1M |
| Returns | |||||
| ROE | 15.5% | 15.5% | 15.3% | 17.1% | 11.9% |
| Valuation | |||||
| P/E | 6.45 | 6.45 | 1.45 | 12.47 | 19.38 |
| EV/EBITDA | 3.79 | 3.79 | 0.24 | 8.24 | 11.10 |
| P/B | 1.00 | 1.00 | 0.22 | 2.13 | 2.31 |
| Growth & Yield | |||||
| Revenue Growth | 15.8% | 15.8% | 2.8% | 10.7% | — |
| EPS Growth | -76.7% | -76.7% | 453.1% | 62.9% | — |
| Dividend Yield | 2.3% | 2.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-17.0%
EPS terminal req.
$534.17
Spread vs growth
-59.8%
5Y implied EPS CAGR
-7.1%
EPS terminal req.
$646.35
Spread vs growth
-69.7%
10Y implied EPS CAGR
1.1%
EPS terminal req.
$1040.96
Spread vs growth
-77.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+6.5%
Start / end P/E
1.4x → 6.5x
EPS bridge
4010.00 → 933.00
Residual
-267.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.